Creo Medical Reports 45% Revenue Growth, Narrows Operating Loss in First Half

Creo Medical, a medical device manufacturer based in the United Kingdom, reported a 45% increase in revenue to £3.2 million for the first half of 2026 compared to the same period last year. The company also demonstrated significant progress in operational efficiency, reducing its operating loss by more than 25%.

Key Financials and Operations

In its half-year report, Creo Medical detailed strong top-line growth alongside disciplined cost management. The company successfully lowered its operating costs by 15% over the six-month period.

Management attributed the revenue increase to the growing adoption of its core product portfolio, which includes devices such as Speedboat, SpydrBlade Flex, and MicroBlate Fine. Geographic expansion, particularly into new markets in Latin America, also contributed to the sales growth.

Ad

Cost Reduction and Outlook

Creo Medical's cost-cutting initiatives included scaling its commercial platform, simplifying business operations, and outsourcing certain manufacturing activities. These measures, combined with recent financing, are intended to support the company's move toward profitability, according to its statement.

Despite the strong first-half performance, the company maintained its full-year revenue growth guidance of 50% to 60%. Management expressed confidence in this forecast, citing a strong order book and expectations for revenue to be weighted toward the second half of the year.